Trial Profile
A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroquel XR) Dosed Once Daily in the Evening in Patients With Stable Schizophrenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacodynamics
- Acronyms eXtRa
- Sponsors AstraZeneca
- 18 Oct 2012 Planned number of patients changed from 90 to 100 as reported by EudraCT.
- 17 Oct 2012 Patient-reported outcomes presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
- 26 Jul 2012 Primary endpoint added as reported by ClinicalTrials.gov.